Aviragen Therapeutics (AVIR) Tops Q2 EPS by 13c

Aviragen Therapeutics (NASDAQ: AVIR) reported Q2 EPS of ($0.34), $0.13 better than the analyst estimate of ($0.47). Revenue for the quarter came in at $0 versus the consensus estimate of $0 .

For earnings history and earnings-related data on Aviragen Therapeutics (AVIR) click here.

You May Also Be Interested In

• KB Home (KBH) Tops Q3 EPS by 16c
• AutoZone (AZO) Tops Q4 EPS by $1.76, Misses on Revenue
• Jefferies Starts China Oilfield Services (A-Shares) (601808:CH) at Buy